Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity Testing.

Autor: Behrens D; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Pfohl U; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany.; CELLphenomics GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Conrad T; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Becker M; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Brzezicha B; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Büttner B; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Wagner S; Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, 72076 Tübingen, Germany., Hallas C; Institut für Hämatopathologie, Fangdieckstr. 75, 22547 Hamburg, Germany., Lawlor R; ARC-Net Research Center, University and Hospital Trust of Verona, Piazzale A. Scuro 10, 37134 Verona, Italy., Khazak V; NexusPharma, 17 Black Forest Rd., Hamilton, NJ 08691, USA., Linnebacher M; Clinic of General Surgery, Molecular Oncology and Immunotherapy, University Medical Center Rostock, 18057 Rostock, Germany., Wartmann T; University Clinic for General, Visceral, Vascular and Transplantation Surgery, Faculty of Medicine, Otto-von-Guericke-University, 39120 Magdeburg, Germany., Fichtner I; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Hoffmann J; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Dahlmann M; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Walther W; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany.; Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, Lindenberger Weg 80, 13125 Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin, Germany.

Publikováno v: Cancers [Cancers (Basel)] 2023 Dec 08; Vol. 15 (24). Date of Electronic Publication: 2023 Dec 08.

32 (PB022) - Humanized mouse models for preclinical evaluation of novel immune therapies, checkpoint inhibitors and immune cell engagers

Autor: Stecklum, M., Brzezicha, B., Rhein, S., Walther, W., Hoffmann, J.

Publikováno v: In European Journal of Cancer October 2022 174 Supplement 1:S12-S12

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.

Autor: Demel UM; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany., Böger M; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Yousefian S; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Grunert C; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Zhang L; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Hotz PW; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Gottschlich A; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany., Köse H; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Isaakidis K; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Vonficht D; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Grünschläger F; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Rohleder E; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Wagner K; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Dönig J; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Igl V; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany., Brzezicha B; Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Berlin, Germany., Baumgartner F; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany., Habringer S; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany., Löber J; Department of Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany., Chapuy B; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany., Weidinger C; Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Kobold S; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany.; German Center for Translational Cancer Research (DKTK), DKFZ, Heidelberg, Germany.; DKTK, Partner Site Munich, Munich, Germany.; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany., Haas S; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Busse AB; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Müller S; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Wirth M; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; German Center for Translational Cancer Research (DKTK), DKFZ, Heidelberg, Germany., Schick M; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Keller U; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; German Center for Translational Cancer Research (DKTK), DKFZ, Heidelberg, Germany.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2022 May 02; Vol. 132 (9).

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.

Autor: Çınar Ö; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany oezcan.cinar@charite.de.; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Brzezicha B; Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Berlin, Germany., Grunert C; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Kloetzel PM; Institute of Biochemistry, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Beier C; Institute of Biochemistry, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Peuker CA; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Keller U; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Pezzutto A; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Busse A; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jul; Vol. 9 (7).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.